MFN2 ameliorates cell apoptosis in a cellular model of Parkinson's disease induced by rotenone

Yang,Yang; Xue,Liu‑Jun; Xue,Xiao; Ou,Zhou; Jiang,Teng; Zhang,Ying‑Dong

doi:10.3892/etm.2018.6595

MFN2 ameliorates cell apoptosis in a cellular model of Parkinson's disease induced by rotenone

Authors:
- Yang Yang
- Liu‑Jun Xue
- Xiao Xue
- Zhou Ou
- Teng Jiang
- Ying‑Dong Zhang
View Affiliations

Affiliations: Department of Neurology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu 210006, P.R. China
Published online on: August 10, 2018 https://doi.org/10.3892/etm.2018.6595
Pages: 3680-3685

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A number of studies indicated that apoptosis, a specific type of programmed cell death, contributed to the loss of dopaminergic neurons during progression of Parkinson's disease (PD). Previously, the authors of the present study demonstrated that apoptosis of dopaminergic neurons was mainly achieved via the mitochondria‑mediated apoptosis pathway, however, the precise molecular mechanisms remain to be elucidated. The present study aimed to determine whether mitofusin‑2 (MFN2), a mitochondrial protein, participated in the apoptosis of dopaminergic neurons in a cellular model of PD induced by rotenone. The present study demonstrated that the expression of MFN2 was relatively stable following treatment with rotenone. Lentiviral knockdown and overexpression experiments for the first time, to the best of the authors knowledge, revealed that MFN2 prevented rotenone‑induced cell death by amelioration of apoptosis. These results revealed a protective role of MFN2 against apoptosis in an in vitro model of PD and may be used to establish MFN2 as a potential therapeutic target for the treatment of this disease.

View Figures

View References

1	Tysnes OB and Storstein A: Epidemiology of Parkinson's disease. J Neural Transm (Vienna). 124:901–905. 2017. View Article : Google Scholar : PubMed/NCBI
2	Schapira AH: Neurobiology and treatment of Parkinson's disease. Trends Pharmacol Sci. 30:41–47. 2009. View Article : Google Scholar : PubMed/NCBI
3	Gao Q, Jiang T, Zhao HR, Wu L, Tian YY, Ou Z, Zhang L, Pan Y, Lu J and Zhang YD: Activation of autophagy contributes to the Angiotensin II-triggered apoptosis in a dopaminergic neuronal cell line. Mol Neurobiol. 53:2911–2919. 2016. View Article : Google Scholar : PubMed/NCBI
4	Zhao HR, Jiang T, Tian YY, Gao Q, Li Z, Pan Y, Wu L, Lu J and Zhang YD: Angiotensin II triggers apoptosis via enhancement of NADPH Oxidase-dependent oxidative stress in a dopaminergic neuronal cell line. Neurochem Res. 40:854–863. 2015. View Article : Google Scholar : PubMed/NCBI
5	Green DR and Llambi F: Cell death signaling. Cold Spring Harb Perspect Biol. 7:pii: a0060802015. View Article : Google Scholar
6	Ou Z, Jiang T, Gao Q, Tian YY, Zhou JS, Wu L, Shi JQ and Zhang YD: Mitochondrial-dependent mechanisms are involved in angiotensin II-induced apoptosis in dopaminergic neurons. J Renin Angiotensin Aldosterone Syst. 17:pii2016. View Article : Google Scholar
7	Schrepfer E and Scorrano L: Mitofusins, from mitochondria to metabolism. Mol Cell. 61:683–694. 2016. View Article : Google Scholar : PubMed/NCBI
8	de Brito OM and Scorrano L: Mitofusin 2: A mitochondria-shaping protein with signaling roles beyond fusion. Antioxid Redox Signal. 10:621–633. 2008. View Article : Google Scholar : PubMed/NCBI
9	Zorzano A, Hernández-Alvarez MI, Sebastián D and Muñoz JP: Mitofusin 2 as a driver that controls energy metabolism and insulin signaling. Antioxid Redox Signal. 22:1020–1031. 2015. View Article : Google Scholar : PubMed/NCBI
10	Stuppia G, Rizzo F, Riboldi G, Del Bo R, Nizzardo M, Simone C, Comi GP, Bresolin N and Corti S: MFN2-related neuropathies: Clinical features, molecular pathogenesis and therapeutic perspectives. J Neurol Sci. 356:7–18. 2015. View Article : Google Scholar : PubMed/NCBI
11	Shi Y, Yi C, Li X, Wang J, Zhou F and Chen X: Overexpression of Mitofusin2 decreased the reactive astrocytes proliferation in vitro induced by oxygen-glucose deprivation/reoxygenation. Neurosc Lett. 639:68–73. 2017. View Article : Google Scholar
12	Wang X, Su B, Lee HG, Li X, Perry G, Smith MA and Zhu X: Impaired balance of mitochondrial fission and fusion in Alzheimer's disease. J Neurosci. 29:9090–9103. 2009. View Article : Google Scholar : PubMed/NCBI
13	Wu L, Luo N, Zhao HR, Gao Q, Lu J, Pan Y, Shi JP, Tian YY and Zhang YD: Salubrinal protects against rotenone-induced SH-SY5Y cell death via ATF4-parkin pathway. Brain Res. 1549:52–62. 2014. View Article : Google Scholar : PubMed/NCBI
14	Jiang T, Tan L, Zhu XC, Zhang QQ, Cao L, Tan MS, Gu LZ, Wang HF, Ding ZZ, Zhang YD and Yu JT: Upregulation of TREM2 ameliorates neuropathology and rescues spatial cognitive impairment in a transgenic mouse model of Alzheimer's disease. Neuropsychopharmacology. 39:2949–2962. 2014. View Article : Google Scholar : PubMed/NCBI
15	Lu J, Wu L, Jiang T, Wang Y, Zhao H, Gao Q, Pan Y, Tian Y and Zhang Y: Angiotensin AT2 receptor stimulation inhibits activation of NADPH oxidase and ameliorates oxidative stress in rotenone model of Parkinson's disease in CATH.a cells. Neurotoxicol Teratol. 47:16–24. 2015. View Article : Google Scholar : PubMed/NCBI
16	Jiang T, Zhang YD, Chen Q, Gao Q, Zhu XC, Zhou JS, Shi JQ, Lu H, Tan L and Yu JT: TREM2 modifies microglial phenotype and provides neuroprotection in P301S tau transgenic mice. Neuropharmacology. 105:196–206. 2016. View Article : Google Scholar : PubMed/NCBI
17	Jiang T, Zhang YD, Gao Q, Zhou JS, Zhu XC, Lu H, Shi JQ, Tan L, Chen Q and Yu JT: TREM1 facilitates microglial phagocytosis of amyloid beta. Acta Neuropathol. 132:667–683. 2016. View Article : Google Scholar : PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
19	Johnson ME and Bobrovskaya L: An update on the rotenone models of Parkinson's disease: Their ability to reproduce the features of clinical disease and model gene-environment interactions. Neurotoxicology. 46:101–116. 2015. View Article : Google Scholar : PubMed/NCBI
20	Bombelli F, Stojkovic T, Dubourg O, Echaniz-Laguna A, Tardieu S, Larcher K, Amati-Bonneau P, Latour P, Vignal O, Cazeneuve C, et al: Charcot-Marie-Tooth disease type 2A: From typical to rare phenotypic and genotypic features. JAMA Neurol. 71:1036–1042. 2014. View Article : Google Scholar : PubMed/NCBI
21	Peng C, Rao W, Zhang L, Wang K, Hui H, Wang L, Su N, Luo P, Hao YL, Tu Y, et al: Mitofusin 2 ameliorates hypoxia-induced apoptosis via mitochondrial function and signaling pathways. Int J Biochem Cell Biol. 69:29–40. 2015. View Article : Google Scholar : PubMed/NCBI
22	Park J, Choi H, Min JS, Kim B, Lee SR, Yun JW, Choi MS, Chang KT and Lee DS: Loss of mitofusin 2 links beta-amyloid-mediated mitochondrial fragmentation and Cdk5-induced oxidative stress in neuron cells. J Neurochem. 132:687–702. 2015. View Article : Google Scholar : PubMed/NCBI
23	Zhao F, Wang W, Wang C, Siedlak SL, Fujioka H, Tang B and Zhu X: Mfn2 protects dopaminergic neurons exposed to paraquat both in vitro and in vivo: Implications for idiopathic Parkinson's disease. Biochim Biophy Acta. 1863:1359–1370. 2017. View Article : Google Scholar